Literature DB >> 10768522

Comparison of granisetron, ondansetron and tropisetron for control of vomiting and nausea induced by cisplatin.

A Oge1, N Alkiş, O Oge, A Kartum.   

Abstract

Severe nausea and vomiting are common and one of the most feared side effects of cisplatin-based chemotherapy. A total of 106 patients were randomized to receive a single dose of 8 mg ondansetron or 3 mg granisetron or 5 mg tropisetron intravenously as prevention of cisplatin-induced acute nausea and vomiting. Antiemetic therapy was done within 30 minutes before initiating chemotherapy. A questionnaire evaluating nausea, vomiting and retches was administered to patients and the responses were categorized as complete, partial or failure. The response determination was repeated in the first 24 hours, and within 24-72 hours following cisplatin administration. The complete response rates for ondansetron, granisetron and tropisetron in the first 24 hours were 51.4%, 65.7% and 61.1% respectively. All three agents were highly effective against cisplatin-induced acute and late vomiting and the results were statistically significant. This study demonstrated no significant difference in effectiveness of these three antiemetics. 5-HT3 (5-hydroxytryptamine 3) receptor antagonists have similar efficacy in the prevention of nausea and vomiting due to cisplatin. Thus, we recommend that drug choice be based on cost-benefit and patient tolerance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768522     DOI: 10.1179/joc.2000.12.1.105

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  4 in total

1.  Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis.

Authors:  Karin Jordan; Axel Hinke; Axel Grothey; Hans Joachim Schmoll
Journal:  Support Care Cancer       Date:  2004-11-18       Impact factor: 3.603

Review 2.  Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.

Authors:  Vanessa Piechotta; Anne Adams; Madhuri Haque; Benjamin Scheckel; Nina Kreuzberger; Ina Monsef; Karin Jordan; Kathrin Kuhr; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2021-11-16

3.  Phase II clinical trial of palonosetron combined with tropisetron in preventing chemotherapy-induced nausea and vomiting.

Authors:  Yuan Ma; Lei Su; Liyan Liu; Chao Xie; Xia Zhang; Bao Song; Sensen Cheng; Jie Liu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

4.  A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.

Authors:  K Jordan; A Hinke; A Grothey; W Voigt; D Arnold; H-H Wolf; H-J Schmoll
Journal:  Support Care Cancer       Date:  2007-01-05       Impact factor: 3.359

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.